版本:
中国

BRIEF-Morphosys, Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis

Sept 29 Morphosys Ag

* Says Morphosys and Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis

* Says favorable safety results shown in healthy volunteers receiving single ascending doses (SAD) in study to date Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐